The Relative Strength (RS) Rating for Incyte jumped into a higher percentile Wednesday, as it got a lift from 61 to 79.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's unique rating measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners often have an 80 or higher RS Rating as they launch their biggest price moves. See if Incyte can continue to rebound and clear that threshold.
Incyte is building a consolidation with an 83.95 buy point. See if the stock can break out in volume at least 40% higher than normal.
Incyte posted 0% EPS growth in the latest quarterly report, while sales growth came in at 16%.
Incyte earns the No. 1 rank among its peers in the Medical-Biomed/Biotech industry group. Inhibrx Biosciences and Kiniksa Pharmaceuticals are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
